The war against HCQ has intensified unbelievably
- Thread starter Nehemiah6
- Start date
-
Christian Chat is a moderated online Christian community allowing Christians around the world to fellowship with each other in real time chat via webcam, voice, and text, with the Christian Chat app. You can also start or participate in a Bible-based discussion here in the Christian Chat Forums, where members can also share with each other their own videos, pictures, or favorite Christian music.
If you are a Christian and need encouragement and fellowship, we're here for you! If you are not a Christian but interested in knowing more about Jesus our Lord, you're also welcome! Want to know what the Bible says, and how you can apply it to your life? Join us!
To make new Christian friends now around the world, click here to join Christian Chat.
I think you mean not in here....correct?
I have access to all Publications and Journals through my work.
Some of the less reputable ones can be accessed on line.
I can send you a link via PM later when on my computer.
I have access to all Publications and Journals through my work.
Some of the less reputable ones can be accessed on line.
I can send you a link via PM later when on my computer.
-
1
- Show all
That the hogwash about HCQ being found non-effective in clinical trials? Well then, you did learn something from science in here. Bravo. Though you'd have to search for where those peer reviewed links appear, in here.
Though you'd have to search for where those peer reviewed links appear, in here.
You are right, HQC is very effective, for LUPUS...
-
1
- Show all
That too. As well as malaria and rheumatoid arthritis. As well as Coronavirus Covid 19. peer review studies HCQ covid 19
https://www.medrxiv.org/content/medrxiv/early/2020/03/30/2020.03.22.20040758.full.pdf
Zhaowei Chen1, , Jijia Hu1, , Zongwei Zhang1 , Shan Jiang2 , Shoumeng Han3 , Dandan Yan4 , Ruhong Zhuang5 , Ben Hu6 and Zhan Zhang7,* 1 Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 2 Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 3 Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China. 4 Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 5 Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 6 CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430060, China. 7 Department II of Respiratory Disease and Intensive Care, Renmin Hospital of Wuhan University, Wuhan 430060, China. Zhaowei Chen and Jijia Hu contributed equally to this work. * Corresponding author: Zhan Zhang, Department II of Respiratory Disease and Intensive Care, Renmin Hospital of Wuhan University, Wuhan 430060, China. Email: [email protected] Abstract Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough It is made available under a CC-BY-NC-ND 4.0 International license . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: https://doi.org/10.1101/2020.03.22.20040758.this version posted March 30, 2020.
The copyright holder for this preprint It is made available under a CC-BY-NC-ND 4.0 International license . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
CQ and its derivatives have been broadly used as immunomodulators in the treatment of systemic lupus erythematosus (SLE) and other rheumatism [12]. As the pharmacological mechanism of CQ is further elucidated, its additional clinical applications, especially the antiviral activity, are also increasingly valued [13]. The efficiency of CQ has been proven in a variety of viruses, including human coronavirus [[14], [15], [16]]. Researchers have even reported both prophylactic and therapeutic advantages of CQ for SARS-CoV infection [17]. The severe acute respiratory syndrome caused by SARS-CoV-2 in several patients is quite similar to SARS-CoV in 2002 and is currently seriously threatening global health by triggering COVID-19. However, none specific drugs are available for the prevention or treatment of COVID-19. Recently, Wang et al. identified that CQ could effectively inhibit the replication and spread of SARS-CoV-2 in vitro [7]. Experts and guides for COVID-19 in China have also recommended chloroquine phosphate superior to the treatment of SARS-CoV-2 infection [8,9].
To assess the safetyand effects of CQ in patients with COVID-19, we registered this trial in ChiCTR and chose HCQ (the sulfate and phosphate salts of CQ) as the intervention agent. The data in this study revealed that after 5 days of HCQ treatment, the symptoms of patients with COVID-19 were significantly relieved, manifesting as shorten in the recovery time for cough and fever. At the same time, a larger proportion of patients with pulmonary inflammatory has been partially absorbed in the HCQ treatment group, indicating the immune modulation and anti-inflammatory properties of HCQ in non-malarial diseases [17]. At present, the multiple actions of HCQ such as regulation in pro-inflammatory cytokines [e.g. Tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-1 (IL-6)], antioxidant activities, also promote it widely performed in rheumatic diseases such as SLE [11,17]. According to current research, a higher pro-inflammatory cytokine storm existed in COVID-19 patients with a severe or critical illness, eventually affected the prognosis [18]. For this, IL-6 antibody blocker, transfusion of convalescent plasma, and other therapies have been applied to counteract the cytokine storm [19,20]. Therefore, with antiviral and autoimmune regulation effects, HCQ should be a protector in SARS-CoV-2 infection. In the present study, the reduced risk of progression to severe illness in patients with HCQ treatment also explained the intervention effect of HCQ on the pathological process of the COVID-19. Although HCQ has proven to be effective, with advantages of inexpensive and easily accessible, its potential detrimental effects in viral diseases must also be taken seriously. Retinopathy is one of the major adverse reactions of long-term therapy with HCQ [21]. Besides, patients with rheumatoid diseases treated with HCQ occasionally experience arrhythmias [22]. Other rare adverse reactions caused by HCQ include gastrointestinal reactions, cramps, liver dysfunction, itching, headache, dizziness, insomnia, peripheral neuropathy [13]. Fortunately, deciding on individual treatment plans scientifically, monitoring adverse reactions timely, to avoid overdose, short-term application of HCQ is relatively safe.
https://www.medrxiv.org/content/medrxiv/early/2020/03/30/2020.03.22.20040758.full.pdf
Zhaowei Chen1, , Jijia Hu1, , Zongwei Zhang1 , Shan Jiang2 , Shoumeng Han3 , Dandan Yan4 , Ruhong Zhuang5 , Ben Hu6 and Zhan Zhang7,* 1 Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 2 Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 3 Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China. 4 Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 5 Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 6 CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430060, China. 7 Department II of Respiratory Disease and Intensive Care, Renmin Hospital of Wuhan University, Wuhan 430060, China. Zhaowei Chen and Jijia Hu contributed equally to this work. * Corresponding author: Zhan Zhang, Department II of Respiratory Disease and Intensive Care, Renmin Hospital of Wuhan University, Wuhan 430060, China. Email: [email protected] Abstract Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough It is made available under a CC-BY-NC-ND 4.0 International license . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: https://doi.org/10.1101/2020.03.22.20040758.this version posted March 30, 2020.
The copyright holder for this preprint It is made available under a CC-BY-NC-ND 4.0 International license . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
CQ and its derivatives have been broadly used as immunomodulators in the treatment of systemic lupus erythematosus (SLE) and other rheumatism [12]. As the pharmacological mechanism of CQ is further elucidated, its additional clinical applications, especially the antiviral activity, are also increasingly valued [13]. The efficiency of CQ has been proven in a variety of viruses, including human coronavirus [[14], [15], [16]]. Researchers have even reported both prophylactic and therapeutic advantages of CQ for SARS-CoV infection [17]. The severe acute respiratory syndrome caused by SARS-CoV-2 in several patients is quite similar to SARS-CoV in 2002 and is currently seriously threatening global health by triggering COVID-19. However, none specific drugs are available for the prevention or treatment of COVID-19. Recently, Wang et al. identified that CQ could effectively inhibit the replication and spread of SARS-CoV-2 in vitro [7]. Experts and guides for COVID-19 in China have also recommended chloroquine phosphate superior to the treatment of SARS-CoV-2 infection [8,9].
To assess the safetyand effects of CQ in patients with COVID-19, we registered this trial in ChiCTR and chose HCQ (the sulfate and phosphate salts of CQ) as the intervention agent. The data in this study revealed that after 5 days of HCQ treatment, the symptoms of patients with COVID-19 were significantly relieved, manifesting as shorten in the recovery time for cough and fever. At the same time, a larger proportion of patients with pulmonary inflammatory has been partially absorbed in the HCQ treatment group, indicating the immune modulation and anti-inflammatory properties of HCQ in non-malarial diseases [17]. At present, the multiple actions of HCQ such as regulation in pro-inflammatory cytokines [e.g. Tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-1 (IL-6)], antioxidant activities, also promote it widely performed in rheumatic diseases such as SLE [11,17]. According to current research, a higher pro-inflammatory cytokine storm existed in COVID-19 patients with a severe or critical illness, eventually affected the prognosis [18]. For this, IL-6 antibody blocker, transfusion of convalescent plasma, and other therapies have been applied to counteract the cytokine storm [19,20]. Therefore, with antiviral and autoimmune regulation effects, HCQ should be a protector in SARS-CoV-2 infection. In the present study, the reduced risk of progression to severe illness in patients with HCQ treatment also explained the intervention effect of HCQ on the pathological process of the COVID-19. Although HCQ has proven to be effective, with advantages of inexpensive and easily accessible, its potential detrimental effects in viral diseases must also be taken seriously. Retinopathy is one of the major adverse reactions of long-term therapy with HCQ [21]. Besides, patients with rheumatoid diseases treated with HCQ occasionally experience arrhythmias [22]. Other rare adverse reactions caused by HCQ include gastrointestinal reactions, cramps, liver dysfunction, itching, headache, dizziness, insomnia, peripheral neuropathy [13]. Fortunately, deciding on individual treatment plans scientifically, monitoring adverse reactions timely, to avoid overdose, short-term application of HCQ is relatively safe.
Conclusion Despite our small number of cases, the potential of HCQ in the treatment of COVID-19 has been partially confirmed. Considering that there is no better option at present, it is a promising practice to apply HCQ to COVID-19 under reasonable management. However, Large-scale clinical and basic research is still needed to clarify its specific mechanism and to continuously optimize the treatment plan.
-
1
-
1
- Show all
Maybe Gates is the antichrist. Consider what we're told the AC's characteristics shall be. How many boxes does BG tick off?
ABSTRACT
Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge. Toxicity concerns have been addressed with updated prescribing recommendations.
ABSTRACT
Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge. Toxicity concerns have been addressed with updated prescribing recommendations.
-
1
- Show all
E
My point is insulin was a generic drug, the patented and put back on market for profit.
So this whole HQC stuff is bogus ... if it was a viable treatment it would have undergone the same process.
Remdesivir is only administered for the most ill and not even used in the same way as a treatment.
So this whole HQC stuff is bogus ... if it was a viable treatment it would have undergone the same process.
Remdesivir is only administered for the most ill and not even used in the same way as a treatment.
-
1
- Show all
That's what they're about isn't it? Disinformation? When there are HCQ peer reviewed papers and viable studies concerning the viability of HCQ with regard to Covid 19, what does anyone need to argue? They're 100% against the proofs off site already. Think about that brother.
New Study Shows That Hydroxychloroquine Saves Lives, States AAPS
A just published peer-reviewed study from Henry Ford Health System showed that the death rate of hospitalized patients who received hydroxychloroquine (HCQ) was cut in half, and there were no serious heart abnormalities.
The Association of American Physicians & Surgeons (AAPS) stated that these results should encourage widespread early use of this long-established drug to fight COVID-19.
“HCQ impressively improved survival. In contrast, the government-favored drug remdesivir has only been shown to decrease survivors’ hospital stay by four days, with no demonstrable improvement in survival,” notes AAPS.
Even before the Henry Ford study, there was substantial evidence of HCQ benefit, especially when used very early in out-patients in combination with zinc, in a compilation of studies prior to April 20, a more recent compilation, and a preprint by Dr. Vladimir Zelenko and colleagues released July 3. Yale epidemiologist Harvey Risch, M.D., wrote that HCQ is an “early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis.”
Based on flawed studies and pronouncements from government officials, doctors have hesitated to use HCQ because of claimed lack of proof of efficacy, or purported danger of cardiac arrhythmias. Two studies, in Lancet and NEJM, were retracted because of questionable data. A study from Brazil, published in JAMA, is under investigation because researchers were giving patients lethal doses of chloroquine.
Researchers have been using HCQ too late, when patients may already have COVID-caused heart damage, and overdosing patients, states AAPS.
“If HCQ saves half the patients who would have died in hospital, then withholding HCQ is causing tens of thousands of preventable deaths,” states AAPS.
“The federal government has agreed to buy 500,000 doses of remdesivir at more than $3,000 per course of treatment, without proof that it will save lives. Why won’t it release HCQ, which costs about $20 per course of treatment, from the Strategic National Stockpile, and stop prohibiting or discouraging its use?” asks AAPS.
“Patients are dying needlessly every day.”
AAPS has filed for a preliminary injunction to stop interference by the FDA with patient access to HCQ, and to prevent the government from wasting the HCQ which was donated to its stockpile. This lawsuit is pending in federal court in Grand Rapids, Michigan, AAPS v. FDA, et al., 20-cv-493.
The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.
Related Video:
New Study Shows That Hydroxychloroquine Saves Lives, States AAPS
A just published peer-reviewed study from Henry Ford Health System showed that the death rate of hospitalized patients who received hydroxychloroquine (HCQ) was cut in half, and there were no serious heart abnormalities.
The Association of American Physicians & Surgeons (AAPS) stated that these results should encourage widespread early use of this long-established drug to fight COVID-19.
“HCQ impressively improved survival. In contrast, the government-favored drug remdesivir has only been shown to decrease survivors’ hospital stay by four days, with no demonstrable improvement in survival,” notes AAPS.
Even before the Henry Ford study, there was substantial evidence of HCQ benefit, especially when used very early in out-patients in combination with zinc, in a compilation of studies prior to April 20, a more recent compilation, and a preprint by Dr. Vladimir Zelenko and colleagues released July 3. Yale epidemiologist Harvey Risch, M.D., wrote that HCQ is an “early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis.”
Based on flawed studies and pronouncements from government officials, doctors have hesitated to use HCQ because of claimed lack of proof of efficacy, or purported danger of cardiac arrhythmias. Two studies, in Lancet and NEJM, were retracted because of questionable data. A study from Brazil, published in JAMA, is under investigation because researchers were giving patients lethal doses of chloroquine.
Researchers have been using HCQ too late, when patients may already have COVID-caused heart damage, and overdosing patients, states AAPS.
“If HCQ saves half the patients who would have died in hospital, then withholding HCQ is causing tens of thousands of preventable deaths,” states AAPS.
“The federal government has agreed to buy 500,000 doses of remdesivir at more than $3,000 per course of treatment, without proof that it will save lives. Why won’t it release HCQ, which costs about $20 per course of treatment, from the Strategic National Stockpile, and stop prohibiting or discouraging its use?” asks AAPS.
“Patients are dying needlessly every day.”
AAPS has filed for a preliminary injunction to stop interference by the FDA with patient access to HCQ, and to prevent the government from wasting the HCQ which was donated to its stockpile. This lawsuit is pending in federal court in Grand Rapids, Michigan, AAPS v. FDA, et al., 20-cv-493.
The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.
Related Video:
-
2
- Show all
You swim through ten ft of water that the government backed scientists assured us by 2007 due to man made global warming if you live near any coast .. Then you find real science data from some one with skin in the game is a good place to start, or whoever gets censored, jailed or murdered ...
-
1
- Show all
You may either not be aware of this, or you may be turning a blind eye to it. The medical journals themselves have been corrupted so that they are deliberately sabotaging HCQ and promoting Remdesivir. You probably never imagined that such a day would come, but since the FDA has also been deliberately sabotaging HCQ. believe it.
And also note that when a string of CHINESE RESEARCHERS are pushing a certain agenda, then it is not science but propaganda. Nothing should be taken at face value any more.
And also note that when a string of CHINESE RESEARCHERS are pushing a certain agenda, then it is not science but propaganda. Nothing should be taken at face value any more.
-
2
-
1
-
1
- Show all
E
You are funny, I will ask my family and friends published in those journals if the research they conducted and published in a variety of medical and science journals were corrupted?
HQC has no science to support it...there is a actually a viral drug moving into clinical trials at the University of Alberta that breaks the long chain protein that will stop the virus from multiplying ..it was started in2003 during the SARS CoV1 that is showing promise.
HQC has no science to support it...there is a actually a viral drug moving into clinical trials at the University of Alberta that breaks the long chain protein that will stop the virus from multiplying ..it was started in2003 during the SARS CoV1 that is showing promise.
-
1
- Show all